Laser transfer for circulating tumor cell isolation in liquid biopsy.

Autor:	Molpeceres C; Centro Láser, Universidad Politécnica de Madrid, Madrid, Spain., Ramos-Medina R; Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), CiberOnc, Madrid, Spain., Marquez A; Centro Láser, Universidad Politécnica de Madrid, Madrid, Spain., Romero P; Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), CiberOnc, Madrid, Spain., Gomez-Fontela M; Centro Láser, Universidad Politécnica de Madrid, Madrid, Spain., Candorcio-Simon R; Centro Láser, Universidad Politécnica de Madrid, Madrid, Spain., Muñoz A; Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), CiberOnc, Madrid, Spain., Lauzurica S; Centro Láser, Universidad Politécnica de Madrid, Madrid, Spain., Del Monte-Millan M; Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), CiberOnc, Madrid, Spain., Morales M; Centro Láser, Universidad Politécnica de Madrid, Madrid, Spain., Muñoz-Martin D; Centro Láser, Universidad Politécnica de Madrid, Madrid, Spain., Lopez-Tarruella S; Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), CiberOnc, Madrid, Spain., Massarrah T; Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), CiberOnc, Madrid, Spain., Martin M; Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), CiberOnc, Madrid, Spain.
Jazyk:	angličtina
Zdroj:	International journal of bioprinting [Int J Bioprint] 2023 Mar 28; Vol. 9 (4), pp. 720. Date of Electronic Publication: 2023 Mar 28 (Print Publication: 2023).
DOI:	10.18063/ijb.720
Abstrakt:	75Cancer research has found in the recent years a formidable ally in liquid biopsy, a noninvasive technique that allows the study of circulating tumor cells (CTCs) and biomolecules involved in the dynamics of cancer spread like cell-free nucleid acids or tumor-derived extracellular vesicles. However, single-cell isolation of CTCs with high viability for further genetic, phenotypic, and morphological characterization remains a challenge. We present a new approach for single CTC isolation in enriched blood samples using a liquid laser transfer (LLT) process, adapted from standard laser direct write techniques. In order to completely preserve the cells from direct laser irradiation, we used an ultraviolet laser to produce a blister-actuated laser-induced forward transfer process (BA-LIFT). Using a plasma-treated polyimide layer for blister generation, we completely shield the sample from the incident laser beam. The optical transparency of the polyimide allows direct cell targeting using a simplified optical setup, in which the laser irradiation module, standard imaging, and fluorescence imaging share a common optical path. Peripheral blood mononuclear cells (PBMCs) were identified by fluorescent markers, while target cancer cells remained unstained. As a proof of concept, we were able to isolate single MDA-MB-231 cancer cells using this negative selection process. Unstained target cells were isolated and culture while their DNA was sent for single-cell sequencing (SCS). Our approach appears to be an effective approach to isolate single CTCs, preserving cell characteristics in terms of cell viability and potential for further SCS. Competing Interests: Andres Muñoz has a consulting or advisory role at Sanofi, Celgene, Pfizer, BMS, Leo Pharma, Astra Zeneca, MSD, Incyte, Servier, Lilly, Roche, and Daiichi Sankyo; is in the Speakers’ Bureau of Rovi, Stada, Menarini, Bayer, Merck Serono, Amgen, Lilly, Astra Zeneca, Sanofi, BMS, Pfizer, and Daiichi Sankyo; and has been sponsored by Roche, Amgen, Merck Serono, Celgene, and Astra Zeneca to cover expenses in travel and accommodations. Sara Lopez-Tarruella has a consulting or advisory role at AstraZeneca, Novartis, Roche, Pfizer, Pierre Fabre, Lilly, Seagen, Daiichi Sankyo, Gilead Sciences, MSD, GlaxoSmithKline and Veracity; and is in the Speakers’ Bureau of Lilly. Miguel Martin has a consulting or advisory role at Roche/Genentech, Novartis, Pfizer, Lilly, AstraZeneca, Taiho Pharmaceutical, and PharmaMar; is in 86the Speakers’ Bureau of Lilly/ImClone, Roche/Genentech, and Pierre Fabre; has received honoraria from Roche/Genentech, Lilly, Pfizer, Novartis, and Pierre-Fabre; and has received research funding from Novartis, Roche, and PUMA. (Copyright: © 2023, Molpeceres C, Ramos-Medina R, Marquez A, et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu